The global intrathecal pumps market size was valued at USD 341.8 million in 2022 and is anticipated to grow at a CAGR of 5.2% from 2023 to 2030. The rising incidence of chronic disorders, such as cancer, back pain, and chronic pancreatitis, is the major factor anticipated to drive the industry's growth. According to the World Health Organization (WHO) report, September 2022, for improvements in overall health, the WHO warned that if the trend of non-communicable diseases continues, in 2050 chronic illnesses such as cancer, cardiovascular disease, and respiratory illnesses will be responsible for 86% of deaths annually.
Technological advancements in intrathecal pumps are expected to boost industry growth. Advancements, such as improvements in pump delivery modes, catheter design, as well as safety features, are predicted to increase its adoption rate. According to a report published by National Centre for Biotechnology Information in June 2022, Intrathecal Drug Delivery Systems (IDDS) are well-known as an effective treatment technique for people suffering from chronic benign pain. Furthermore, it is also treated as a tool for managing patients with severe muscle spasticity and providing therapies that address various spinal diseases.
In addition, manufacturers of intrathecal pumps are also observed to advance devices having longer battery life, which may help minimize the number of future surgical procedures required to replace expiring pumps. Rising cases of pain disorders are projected to drive the market growth. With the rising survival rate for oncologic patients, the occurrence of cancer pain is also growing. Pain arises in 67% of patients with metastatic cancer, which is among the most prevalent symptoms. The majority of chronic cancer pain can be managed with pharmacologic therapies, including analgesia. However, intrathecal drug delivery offers an alternative route of administration for analgesics, which helps reduce side effects with better bioavailability, thereby accelerating the industry growth.
The COVID-19 pandemic moderately impacted industry growth. Pandemic-induced social and healthcare disruptions pose a substantial risk to patients with an intrathecal pump, leading to replacement or refill appointments and severe withdrawal syndrome propelling the market growth. Baclofen is life‐threatening with complications, such as seizure, rhabdomyolysis, coma, and death, creating a challenge in the industry. An increasing number of product launches by prominent companies is estimated to boost industry growth. In June 2022, Amneal Pharmaceuticals announced the launch of LYVISPAH (baclofen) for treating spasticity associated with multiple sclerosis and other spinal cord disorders.
The pain segment held the largest revenue share of 70.6% in 2022. The rising prevalence of chronic and acute disorders, such as chronic pain cancer, and other pain-causing ailments, such as failed back surgery syndrome, is one of the key factors enhancing segment growth. Hence, intrathecal pumps are best suited for individuals suffering from pain-associated disorders.
The pain segment is expected to grow at the fastest CAGR of 5.5% over the forecast period. Several market players are focusing on developing products for the treatment of spasticity. Medtronic’s Intrathecal Baclofen Therapy (ITB) is a treatment that uses Lioresal Intrathecal (baclofen) to be distributed into the fluid around an individual’s spinal cord to manage severe spasticity. In addition, rising cases of stroke across the world are one of the major factors contributing to the segment growth. As per a report published by the American Heart Association, Inc. in February 2022, over the past 30 years, the incidence of stroke among Americans aged 49 and under has risen rapidly.
The morphine segment accounted for the largest revenue share of 31.5% in 2022. Morphine is considered the gold standard in intrathecal drug administration owing to its strong receptor affinity, stability, and extensive drug user experience. Additionally, morphine has received approval for long-term intrathecal pain treatment by the U.S. FDA. Furthermore, long-term intrathecal morphine has fewer side effects as compared to systemic opioids, expecting to spur the growth of this segment. According to WHO, opioids, such as morphine, are regularly prescribed to manage pain. They effectively relieve various types of pain, from acute to chronic conditions. These medications work as specific receptors in the brain and spinal cord, reducing the perception of pain signals.
The bupivacaine segment is expected to grow at the fastest CAGR of 6.6% during the forecast period. Bupivacaine is considered an excellent adjunct medication in intrathecal therapy. Several studies have revealed that bupivacaine synergistically improves the effect of intrathecal opioids when combined, significantly contributing to its growing market share. Bupivacaine allows some patients to reduce their oral opioid usage and minimizes dose escalations of intrathecal opioids. Thus, several advantages associated with bupivacaine are anticipated to secure segment growth.
North America dominated the global intrathecal pump market and accounted for the largest revenue share of 40.1% in 2022. The availability of well-developed primary, secondary, and tertiary care hospitals supported the market growth in the North American region. Moreover, a strong reimbursement network, and favorable government funding, are major factors predicted to foster market growth. The rising collective efforts by key market companies to improve their product portfolio and ensure high-quality standards are expected to surge the demand for intrathecal pumps across this region. The prevalence of cancer in the U.S. continues to rise rapidly, creating an increased demand for effective and advanced intrathecal pumps. According to the American Cancer Society, it was estimated that around 1.8 million new cases of cancer were to be diagnosed across the U.S. in 2020. In addition, the increasing prevalence of back pain is projected to create growth opportunities for intrathecal pumps. According to the American Chiropractic Association, around 80% of the population will experience back pain at some time in their entire life. Europe is expected to experience a significant growth rate during the analysis period. Rising investments in healthcare infrastructure are expected to boost product demand in various pain care centers, thereby driving the regional market growth.
Asia Pacific is expected to grow at the fastest CAGR of 7.0% during the forecast period. A large patient pool in the Asia Pacific is expected to boost product demand. An increasing number of pain care centers in China, Singapore, Japan, and India is expected to boost the adoption of intrathecal pumps. For instance, Singapore Pain Care Center (SPCC) is a pain management center in Southeast Asia that provides an alternative to open surgery. The high prevalence of pain-related disorders, increasing R&D expenditure, and the growing number of pain care centers in the U.S. & Canada contributed considerably to the region’s growth.
The market is highly competitive, and the key players are undertaking various strategies. In October 2020, Flowonix Medical received FDA approval for their Prometra II 40 ml programmable pump used with intrathecal baclofen. This approval allows the company to offer the Prometra system with 40 ml pumps, benefiting cancer patients and expanding the market for the device. The industry players are adopting various strategies, such as mergers & acquisitions, new product developments, joint ventures, and partnerships, to maintain a strong foothold in the global market. For instance, in May 2022, Miratech Medical and Flowonix Medical collaborated to distribute their specific drug delivery products, such as drug infusion pumps.
Market size value in 2023
USD 358.9 million
Revenue forecast in 2030
USD 513.3 million
CAGR of 5.2% from 2023 to 2030
Base year for estimation
2018 - 2021
2023 - 2030
Revenue in USD million and CAGR from 2023 to 2030
Revenue forecast, company ranking, competitive landscape, growth factors, and trends
Type, application, region
North America; Europe; Asia Pacific; Latin America; & MEA
U.S.; Canada; UK; Germany; France; Italy; Spain; Denmark; Sweden; Norway; China; Japan; India; Australia; South Korea; Thailand; Brazil; Mexico; Argentina; Saudi Arabia; South Africa; UAE; Kuwait
Key companies profiled
Medtronic plc; Flowonix; Medallion Therapeutics; Arrow International, Inc.; Tricumed GmbH; Codman & Shurtleff; Smith’s Medical; Teleflex Incorporated
Free report customization (equivalent up to 8 analyst working days) with purchase. Addition or alteration to country, regional & segment scope
Pricing and purchase options
Avail customized purchase options to meet your exact research needs. Explore purchase options
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For the purpose of this study, Grand View Research has segmented the global intrathecal pumps market on the basis of type, application, and region:
Type Outlook (Revenue, USD Million, 2018 - 2030)
Application Outlook (Revenue, USD Million, 2018 - 2030)
Regional Outlook (Revenue, USD Million, 2018 - 2030)
Middle East & Africa
b. The global intrathecal pumps market size was estimated at USD 341.8 million in 2022 and is expected to reach USD 358.9 million in 2023.
b. The global intrathecal pumps market is expected to grow at a compound annual growth rate of 5.2% from 2023 to 2030 to reach USD 513.3 million by 2030.
b. North America dominated the intrathecal pumps market with a share of 40.1% in 2022. This is attributable to the high prevalence of chronic diseases, improved healthcare infrastructure, and the adoption of advanced devices for providing enhanced medical care.
b. Some key players operating in the intrathecal pumps market include Medtronic plc; Flowonix; Medallion Therapeutics; Arrow International, Inc.; Tricumed GmbH; Codman & Shurtleff; Smith’s Medical; Teleflex Incorporated
b. Key factors that are driving the intrathecal pumps market growth include the increasing prevalence of chronic back pain and muscle spasticity, increasing demand for targeted drug delivery systems, and technological advancements in intrathecal pumps.
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities. Contact us now
"The quality of research they have done for us has been excellent."